Evidence map›Paper›PMID 40502441›Full record

ReviewAPL bioengineering2025

Emerging mechanomedicines informed by mechanotransduction along the integrin-cytoskeleton-nucleus axis.

Yuka Yokoyama, Nya Domkam, Hannaneh Kabir, Abdullah Mansour, Shingo Tsukamoto, Ghafar Yerima, Taiji Adachi, Mohammad R K Mofrad

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in APL bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance.Journal of experimental & clinical cancer research : CR · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Stress transmission towards the nucleus of the cell.Frontiers in cell and developmental biology · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuka YokoyamaORCID https://orcid.org/0000-0003-1829-7028
Nya DomkamMolecular Cell Biomechanics Laboratory, Departments of Bioengineering and Mechanical Engineering, University of California, Berkeley, California 94720, USA.ORCID https://orcid.org/0009-0009-6115-092X
Hannaneh KabirMolecular Cell Biomechanics Laboratory, Departments of Bioengineering and Mechanical Engineering, University of California, Berkeley, California 94720, USA.ORCID https://orcid.org/0009-0004-2817-9548
Abdullah MansourMolecular Cell Biomechanics Laboratory, Departments of Bioengineering and Mechanical Engineering, University of California, Berkeley, California 94720, USA.ORCID https://orcid.org/0009-0007-4806-6972
Shingo TsukamotoMolecular Cell Biomechanics Laboratory, Departments of Bioengineering and Mechanical Engineering, University of California, Berkeley, California 94720, USA.ORCID https://orcid.org/0009-0009-2970-3387
Ghafar YerimaMolecular Cell Biomechanics Laboratory, Departments of Bioengineering and Mechanical Engineering, University of California, Berkeley, California 94720, USA.ORCID https://orcid.org/0009-0003-5292-8505
Taiji AdachiORCID https://orcid.org/0000-0001-5280-4156
Mohammad R K MofradORCID https://orcid.org/0000-0001-7004-4859

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mechanical forces are fundamental to the formation of normal biological tissues and the maintenance of physiological health. These forces are transmitted from the extracellular environment to the cell interior through cell-cell and cell-ECM interactions, the cytoskeleton, the LINC complex, the nuclear pore complex, and chromatin, ultimately regulating gene expression via transcription factors. This process, known as mechanotransduction, enables cells to convert mechanical signals into biochemical responses. Due to its critical role in various cellular functions and its influence on disease progression, mechanotransduction emerges as a potential therapeutic target for a range of conditions, including cancer and cardiovascular diseases, by integrating it with biochemistry, molecular biology, and genetics. Mechanomedicine, a burgeoning field, seeks to harness insights from mechanobiology to develop innovative diagnostic and therapeutic strategies. By targeting the molecular and cellular mechanisms underlying mechanotransduction, mechanomedicine aims to create more effective and precise treatments. Despite the potential, current clinical practices largely depend on conventional therapies like chemotherapy, underscoring the challenges of manipulating mechanotransducive pathways within living organisms. This review bridges fundamental mechanotransduction mechanisms with emerging therapeutic approaches, highlighting how mechanomedicine can revolutionize clinical practice. It explores the latest advancements in targeting mechanotransducive elements, discusses the therapeutic efficacy demonstrated in preclinical and clinical studies, and identifies future directions for integrating mechanobiological principles into medical treatments. By connecting basic mechanobiology with clinical applications, mechanomedicine holds the promise of offering targeted and reliable treatment options, ultimately transforming the landscape of disease management and patient care.

Identifiers

PMID40502441
PMCPMC12158467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.